Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas

Journal of Pathology

Volumn 198, Issue 4, 2002, Pages 435-441

  Chapple, Keith S ^a   Scott, Nigel ^a   Guillou, Pierre J ^a   Coletta, P Louise ^a   Hull, Mark A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CYCLOOXYGENASE 2;

ADENOMA; ANGIOGENESIS; ARTICLE; CARCINOGENICITY; COLORECTAL TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; MACROPHAGE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR GROWTH; TUMOR VOLUME;

ADENOMA; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; ISOENZYMES; MACROPHAGES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036900436     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1223     Document Type: Article

References (41)

1. Bossi P, Viale G, Lee AKC, Alfano R-M, Coggi G, Bosari S. Angiogenesis in colorectal tumours: microvessel quantification in adenomas and carcinomas with clinicopathological correlations. Cancer Res 1995; 55: 5049-5053.
2. Aotake T, Lu C-D, Chiba Y, Muraoka R, Tanigawa N. Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res 1999; 5: 135-142.
3. Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 1994; 37: 921-926.
4. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995; 222: 695-699.
5. Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N, O'Malley FP. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996; 20: 1260-1265.
6. Takebayashi Y, Akiyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996; 78: 226-231.
7. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132: 541-546.
8. Tanigawa N, Amaya H, Matsumura M, et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997; 57: 1043-1046.
9. Vermeulen PB, Van den Eynden GG, Huget P, et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999; 79: 316-322.
10. Gallego MG, Acenero MJF, Ortega JS, Aljama A. Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J Cancer 2000; 36: 55-60.
11. Δ716 mouse intestinal polyps. Cancer Res 2002; 62: 506-511.
12. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
13. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705 -4708.
14. Jacoby RE, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 5040-5044.
15. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733-1740.
16. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
17. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
18. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469-1477.
19. Hull MA, Thomson JL, Hawkey CJ. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut 1999; 45: 529-536.
20. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
21. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-1594.
22. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83: 470-475.
23. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156: 545-553.
24. Hardwick JC, van der Brink GR, Offerhaus GJ, van Deventer SJH, Peppelenbosch MP. NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 2001; 20: 819-827.
25. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474-2484.
26. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6: 4064-4068.
27. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121: 1339-1347.
28. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6: 135-138.
29. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999; 59: 4574-4577.
30. Ghosh AK, Hirasawa N, Niki H, Ohuchi K. Cyclooxygenase-2-mediated angiogenesis in carrageenin-induced granulation tissue in rats. J Pharmacol Exp Ther 2000; 295: 802-809.
31. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 199 1; 146: 108-113.
32. Kodelja V, Müller C, Tenorio S, Schebesch C, Orfanos CE, Goerdt S. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 1997; 197: 478-493.
33. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000; 36: 151-169.
34. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51: 635-642.
35. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410-422.
36. Evans R. Effect of X-irradiation on host-cell infiltration and growth of a murine fibrosarcoma. Br J Cancer 1977; 35: 557-566.
37. Takahashi Y, Bucana CD, Liu W, et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146- 1151.
38. Matsumura M, Chiba Y, Amaya H, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer. Cancer Lett 1998; 128: 55-63.
39. Shomori K, Sakatani T, Goto A, Matsuura T, Kiyonari H, Ito H. Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression. Pathol Int 1999; 49: 491-499.
40. Kaklamanis L, Kakolyris S, Koukourakis M, Gatter KC, Harris AL. From hyperplasia to neoplasia and invasion: angiogenesis in the colorectal adenoma-carcinoma model. Adv Exp Med Biol 2000; 476: 249-266.
41. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001; 2: 278-289.